DarioHealth Corp.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $22.4M | $27.0M | $20.4M | $27.7M | $20.5M |
| Cost of revenue | $9.7M | $13.8M | $14.4M | $18.0M | $16.6M |
| Gross profit | $12.7M | $13.3M | $6.0M | $9.7M | $4.0M |
| Research and development | $13.8M | $24.2M | $20.2M | $19.6M | $17.2M |
| Operating expenses | $49.3M | $71.0M | $62.2M | $66.5M | $80.5M |
| Operating income | -$36.7M | -$57.7M | -$56.2M | -$56.8M | -$76.5M |
| Interest expense | $3.0M | — | — | — | — |
| Pretax income | -$41.6M | -$44.6M | -$59.4M | -$62.2M | -$76.7M |
| Income tax expense | $105,000 | -$1.9M | $64,000 | $4,000 | $32,000 |
| Net income | -$41.7M | -$42.7M | -$59.4M | -$62.2M | -$76.8M |
| Balance Sheet | |||||
| Cash and equivalents | $21.8M | $27.8M | $36.8M | $49.4M | $35.8M |
| Current assets | $35.1M | $40.5M | $47.3M | $65.5M | $45.6M |
| Total assets | $110.1M | $118.9M | $96.4M | $119.2M | $100.8M |
| Current liabilities | $9.3M | $16.6M | $12.5M | $19.4M | $14.4M |
| Stockholders' equity | $67.9M | $72.0M | $58.1M | $80.0M | $85.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$25.9M | -$38.6M | -$30.4M | -$47.8M | -$50.4M |
| Depreciation and amortization | $307,000 | $1.3M | $473,000 | $356,000 | $282,000 |
| Stock-based compensation | $9.4M | $46,000 | $19.7M | $17.0M | $25.0M |
| Capital expenditure | $142,000 | $138,000 | $584,000 | $442,000 | $261,000 |
| Free cash flow | -$26.1M | -$38.7M | -$31.0M | -$48.3M | -$50.7M |
| Share repurchases | — | — | — | $134,000 | — |
| Impairments | $0 | $860,000 | $0 | $0 | $0 |
Shares outstanding 7.3M · Free float 60.4%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.